Please login to the form below

Not currently logged in
Email:
Password:

Precision medicine

This page shows the latest Precision medicine news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters radioligand therapy pipeline with new licence agreement

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs. ... Radioligand therapies have emerged as a new potential class of precision oncology drugs.

Latest news

  • Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

    177Lu-PSMA-617 is a type of precision medicine that combines a targeting compound – ligand – and a therapeutic radioisotope. ... This groundbreaking data confirms our belief in the potential of 177Lu-PSMA-617 to reimagine outcomes for these patients

  • Servier to acquire Agios’ oncology business in $1.8bn deal Servier to acquire Agios’ oncology business in $1.8bn deal

    area. “The strategic acquisition of Agios’ oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognised player in oncology and further supports our

  • AstraZeneca to acquire Alexion for $39bn AstraZeneca to acquire Alexion for $39bn

    programmes. AZ hopes to combine its own precision medicine expertise with Alexion’s specialist rare disease knowledge to leverage its capabilities in a number of therapy areas, including haematology, nephrology, neurology, ... We look forward to

  • 20/20 vision 20/20 vision

    Pharmaceutical communicators will also need to adapt their skills and approaches with the increasing demands of drug development, combined with the personalisation of therapies for rare diseases, as well as precision ... medicine responding to genomic

  • FDA clears Blueprint’s $32k-per-month GI cancer drug FDA clears Blueprint’s $32k-per-month GI cancer drug

    The approval “ushers in a new era of precision medicine in this disease,” according to NAVIGATOR investigator Michael Heinrich of Oregon Health &Science University in the US. ... benefits of this promising new medicine”.

More from news
Approximately 3 fully matching, plus 40 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 19 fully matching, plus 18 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics